|
November 14, 2024
|
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
|
|
November 7, 2024
|
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
|
|
October 29, 2024
|
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
October 28, 2024
|
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
|
|
October 14, 2024
|
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
|
|
October 7, 2024
|
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
|
|
September 30, 2024
|
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
|
|
September 9, 2024
|
Biora Therapeutics Achieves ISO 13485 Certification
|
|
August 28, 2024
|
Biora Therapeutics Announces Positive Nasdaq Listing Decision
|
|
August 26, 2024
|
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|